文献速递神经肌肉病

Neurofascin-155免疫球蛋白亚型:临床病理关联与神经结局

Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
PubMed 文献 · Neurology · 2021-10-11

该研究在Mayo Clinic检测神经病患者血清中的NF155-IgG4、NF155-IgG和NF155-IgM自身抗体,回顾32例血清阳性病例的临床资料。结果显示NF155-IgG4阳性患者具有独特的临床-电诊断特征,表现为远端为主的肌无力、感觉症状和步态共济失调,长期免疫治疗结局良好。

要点

  • NF155-IgG4阳性患者具有独特表型:远端为主肌无力、感觉症状、步态共济失调。
  • NF155-IgG4阳性患者颅神经受累占55%,视乳头水肿占33%。
  • 多数NF155-IgG4患者需二线或三线免疫抑制,但长期结局良好。

核心结论

  • NF155-IgG4阳性患者具有独特的临床-电诊断特征,不同于NF155-IgM或NF155-IgG阳性患者。
  • NF155-IgG4阳性患者就诊时常见神经病理性疼痛和自主神经功能障碍,与典型CIDP不同。
  • NF155-IgG4阳性患者长期免疫治疗结局良好。

研究设计与样本

  • 在Mayo Clinic对神经病患者血清检测NF155-IgG4、NF155-IgG和NF155-IgM自身抗体。
  • 回顾所有血清阳性病例的人口学和临床数据,共鉴定32例NF155病例(25例NF155-IgG阳性,其中20例NF155-IgG4阳性;7例NF155-IgM血清阳性)。

主要发现

  • NF155-IgG4血清阳性患者临床表现为远端重于近端的肌无力、感觉症状(针刺感、不对称感觉异常、神经病理性疼痛)和步态共济失调。
  • 颅神经受累占11/20(55%),视乳头水肿占4/12(33%)。
  • 电诊断检查显示脱髓鞘性多发性神经根神经病占19/20(95%)。
  • 自主神经受累发生率为45%(n=9,复合自主神经评分量表中位评分3.5,范围1-7)。
  • NF155-IgG4患者神经活检(n=11)显示成群节段性脱髓鞘(50%)、髓鞘重复(45%)和结旁肿胀(50%)。

关键数值与推荐

  • NF155-IgG4阳性患者中,颅神经受累为11/20(55%),视乳头水肿为4/12(33%)。
  • 电诊断显示脱髓鞘性多发性神经根神经病为19/20(95%)。
  • 自主神经受累为45%(n=9),复合自主神经评分量表中位评分3.5(范围1-7)。
  • 神经活检(n=11)显示成群节段性脱髓鞘(50%)、髓鞘重复(45%)、结旁肿胀(50%)。
  • 与MAG-IgM血清阳性远端获得性脱髓鞘性对称性神经病患者相比,NF155-IgG4阳性患者对免疫治疗反应更好(p < 0.001),长期临床结局优于contactin-1 IgG阳性患者(p = 0.04)。

临床怎么用

  • 对具有远端为主肌无力、感觉症状和步态共济失调的神经病患者,应考虑检测NF155-IgG4抗体。
  • NF155-IgG4阳性患者常需二线或三线免疫抑制治疗,但长期结局良好。

局限性

  • 本研究为回顾性研究,样本量较小(32例NF155病例,其中20例NF155-IgG4阳性)。
  • 证据等级为Class III,提示诊断准确性证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Multiple studies highlighting the diagnostic utility of neurofascin-155 (NF155)-immunoglobulin G4 (IgG4) in chronic demyelinating inflammatory polyradiculoneuropathy (CIDP) have been published. However, few studies comprehensively address the long-term outcomes or clinical utility of NF155-immunoglobulin M (IgM) or NF155-immunoglobulin G (IgG) in the absence of NF155-IgG4. We evaluated phenotypic and histopathologic specificity and differences in outcomes between these NF155 antibody isotypes or IgG subclasses. We also compare NF155-IgG4-seropositive cases to other seropositive demyelinating neuropathies. METHODS: Neuropathy patient sera at Mayo Clinic were tested for NF155-IgG4, NF155-IgG, and NF155-IgM autoantibodies. Demographic and clinical data of all seropositive cases were reviewed. RESULTS: We identified 32 NF155 cases (25 NF155-IgG-positive [20 NF155-IgG4-positive], 7 NF155-IgM-seropositive). NF155-IgG4-seropositive patients clinically presented with distal more than proximal muscle weakness, positive sensory symptoms (prickling, asymmetric paresthesia, neuropathic pain), and gait ataxia. Cranial nerve involvement (11/20 [55%]) and papilledema (4/12 [33%]) occurred in many. Electrodiagnostic testing (EDX) demonstrated demyelinating polyradiculoneuropathy (19/20 [95%]). Autonomic involvement occurred in 45% (n = 9, median composite autonomic scoring scale score 3.5, range 1-7). Nerve biopsies from the NF155-IgG4 patients (n = 11) demonstrated grouped segmental demyelination (50%), myelin reduplication (45%), and paranodal swellings (50%). Most patients needed second- and third-line immunosuppression but had favorable long-term outcomes (n = 18). Among 14 patients with serial EDX over 2 years, all except one demonstrated improvement after treatment. NF155-IgG-positive, NF155-IgG4-negative (NF155-IgG-positive) and NF155-IgM-positive patients were phenotypically different from NF155-IgG4-seropositive patients. Sensory ataxia, neuropathic pain, cerebellar dysfunction, and root/plexus MRI abnormalities were significantly more common in NF155-IgG4-positive compared to myelin-associated glycoprotein (MAG)-IgM neuropathy. Chronic immune sensory polyradiculopathy (CISP)/CISP-plus phenotype was more common among contactin-1 neuropathies compared to NF155-IgG4-positive cases. NF155-IgG4-positive cases responded favorably to immunotherapy compared to MAG-IgM-seropositive cases with distal acquired demyelinating symmetric neuropathy (p < 0.001) and had better long-term clinical outcomes compared to contactin-1 IgG (p = 0.04). DISCUSSION: We report long-term follow-up and clinical outcome of NF155-IgG4 cases. NF155-IgG4 but not IgM or IgG cases have unique clinical-electrodiagnostic signature. We demonstrate NF155-IgG4-positive patients, unlike classical CIDP with neuropathic pain and dysautonomia common at presentation. Long-term outcomes were favorable. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that NF155-IgG4-seropositive patients, compared to patients with typical CIDP, present with distal more than proximal muscle weakness, positive sensory symptoms, and gait ataxia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shelly S, Klein CJ, Dyck PJB, et al. Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. 2021. PMID: 34635556. doi:10.1212/WNL.0000000000012932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。